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Many common treatments for cancer – including radiation therapy (RT) – have the unfortunate side effect of 
promoting the spread of cancer to other organs [1-3].  While the ‘pro-metastatic’ effects of RT have been known 
for some time, it has garnered renewed attention in recent years in part due to the widespread study of 
circulating tumor cells (CTCs).  In hematogenous metastasis, CTCs detach from the primary tumor and spread 
via the blood to other organs and tissues of the body. There are three main hypotheses for RT induced 
metastasis (RTIM) as reviewed in [1]: i) RT causes disruption of the primary tumor and vasculature, which leads 
to immediate shedding of CTCs, iii) RT induces biomolecular changes in tumor cells, such as epithelial to 
mesenchymal transition, leading to increased CTC shedding over time as the tumor cells die, and, iii) Systemic 
effects, such as the elimination of suppressive signaling molecules by the primary tumor resulting in the 
proliferation of existent but previously dormant micro-metastases [3]. 
Our team recently developed a new instrument called ‘Diffuse in vivo Flow Cytometry’ (DiFC; figure 1) [4]. The 
main advantage of DiFC is that it samples large circulating blood volumes (hundreds of µL per minute), allowing 
in vivo detection of very rare CTCs.  DiFC uses specially designed fiber-optic probe bundles with built-in filters 
and lenses for efficient collection of weak fluorescent signals and blocking of tissue autofluorescence.  As 
labeled cells pass through the DiFC field of view, transient fluorescent peaks are detected. A custom signal 
processing algorithm allowed us to determine the number, direction, speed, and depth of circulating cells, and 
reject false alarm signals from motion artifacts. For example, we recently showed that DiFC allowed detection of 
early dissemination of green fluorescent protein (GFP)-labeled multiple myeloma cells in a disseminated 
xenograft model at CTC burdens below 1 cell per mL, as well as rare CTC clusters (fig. 1). 
In this presentation, we first discuss the design and prior validation of the DiFC instrument.  Second, we discuss 
our recent work in application of DiFC to the study of RTIM.  Specifically, we grew sub-cutaneous Lewis Lung 
Carcinoma (LLC) tumors in mice, which are known to aggressively metastasize to the lungs via the vasculature. 
Irradiation of the primary LLC tumors is known to significantly increase pulmonary metastases in this model, by 
as much as a factor of 5 [3].  We performed local RT of LLC tumors with a Small Animal Radiation Research 
Platform (SARRP). We measured CTC and CTC cluster numbers with DIFC in response to single or 
fractionated RT doses, compared to un-irradiated controls. We also monitored metastases in the lungs by BLI 
imaging, weight, and histology.  DiFC revealed that LLC-CTC numbers significantly increased during tumor 
response in RT mice versus controls, and that these correlated with lung tumor burden at sacrifice. We also 
discuss future prospects for the use of DiFC in monitoring CTC response to other therapies.  
Figure 1.  (a) DiFC instrument [4,5] designed to detect fluorescently-labeled CTCs in (b) mouse tail vasculature. 
We used DiFC to study growth of multiple myeloma in a mouse model, which was also monitored by BLI (c-e). 
Increasing numbers of CTCs were detected (f-h) in arterial blood (red arrows) as the (i) disease progressed. 
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